BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas - Wikidata - awgldk - TriplyDB

BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas

BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas

http://www.wikidata.org/entity/Q36493279

about

Role of Biomarkers in the Development of PARP Inhibitors Hereditary risk evaluation for borderline ovarian tumors based on immunohistochemistry Epigenetic, genetic and environmental interactions in esophageal squamous cell carcinoma from northeast India.The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer.Sox2 gene amplification significantly impacts overall survival in serous epithelial ovarian cancer Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency.The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predicts Poor Survival of Breast Carcinoma Patients.Individual and Combined Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predict Shorter Survival of Soft Tissue Sarcoma Patients.Risk prediction model for epithelial ovarian cancer using molecular markers and clinical characteristics.Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer Assessment of PARP protein expression in epithelial ovarian cancer by ELISA pharmacodynamic assay and immunohistochemistry.Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations.BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers.Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.BRCA1/2 Mutations in Salivary Pleomorphic Adenoma and Carcinoma-ex-Pleomorphic Adenoma.Overexpression of BRCA1 or BRCA2 in prostatectomy specimens is predictive of biochemical recurrence after radical prostatectomy.PARP inhibitors: the journey from research hypothesis to clinical approval.[Hereditary breast and ovarian cancer].

P2860

Q26753159-BC1441EC-C051-4A1C-B6E9-DB38A6577AD3 Q34442933-923158B7-8D66-4674-BC28-BF6C0CB28EF5 Q34676175-152B38D6-E7ED-421B-9B28-21A68D209F07 Q34735951-6A912262-033C-4013-9EC4-4DC12690FB16 Q34766184-0293026F-3D37-44D6-A57E-CF70063A8891 Q35104225-44CA6D38-1612-427E-8807-A854A012C304 Q35105594-0AAC58B6-698C-488E-9B13-9FB6191FA707 Q36038008-827739F4-BC23-418E-9C58-7AC907E11F75 Q36137287-B1A7DF18-DC44-4AFE-BE5B-CF8F895F58D7 Q36199823-D33D3BE6-6BE3-4EE8-82F6-C53FCC42456B Q37046405-3F5D1EE8-8B00-434C-B29A-65F8CD2700F2 Q38377713-2BD011D0-DE05-443D-A58E-3E0730AE8240 Q39639274-1D4DD8C3-A4D2-4180-B75A-9B1F2E978BDB Q40074639-516E8AA4-6CD7-443E-B235-4EC63465F4B1 Q41470948-4BAA4AC1-9ECE-48CD-8711-B505C3BDE07D Q47101613-D4F30B10-78E3-4ACA-865F-3072C4744EAB Q48146508-1DC6B04B-8701-4F61-8FAD-D2CA695CD3F1 Q53682668-B5CE4EC4-3670-49CF-8B4F-B7350EA836DD Q53738265-D7000D8A-F557-41AF-8C71-37955A81A4AC

P2860

BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas

http://www.wikidata.org/entity/Q36493279

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

BRCA1 immunohistochemistry in ...... n high-grade serous carcinomas

@ast

BRCA1 immunohistochemistry in ...... n high-grade serous carcinomas

@en

type

label

BRCA1 immunohistochemistry in ...... n high-grade serous carcinomas

@ast

BRCA1 immunohistochemistry in ...... n high-grade serous carcinomas

@en

prefLabel

BRCA1 immunohistochemistry in ...... n high-grade serous carcinomas

@ast

BRCA1 immunohistochemistry in ...... n high-grade serous carcinomas

@en

P1433

Q36493279-5DC17993-DAD1-47E9-9ED9-6DEA42CB248E

P1476

Q36493279-F5E10510-8E92-4273-9FED-6D7BF9F7EF73

P2093

Q36493279-0A98C4A4-CCE3-4753-A6F8-F6CE451BE5F5

Q36493279-135A9C94-98CB-4F28-96CE-5C6A55AA4C0E

Q36493279-27633A6A-4336-4C26-B24B-15A68FA6BD45

Q36493279-C96BDA33-74EA-4522-9B80-4FE68F2A949A

Q36493279-CCA5B161-BCE2-47B5-B41A-A62748081B87

Q36493279-D0C685E9-FCD8-4D2D-8C32-75BCBD9CD33F

Q36493279-E47CE6B6-E80E-4DBC-AEA6-2D1E82B05185

Q36493279-EBE604FB-0722-447A-99CF-941C4D571C1E

P2860

Q36493279-09DD3AD2-7B81-4308-B3E5-EC3370B44586

Q36493279-12136A79-809E-4B71-A923-7D6F0F6C6F88

Q36493279-1486D4E5-2E45-4650-8CE5-E9CEC19197B7

Q36493279-1ADC427E-9235-4049-A7FA-100C98468580

Q36493279-2A0C2A61-4BEE-4F04-BC55-4390DBD6C4FD

Q36493279-38FE1EA2-5EB7-42EC-8F8E-C2A3948835CE

Q36493279-48A4136A-0244-4541-9B8A-BDB6BD72D822

Q36493279-5B793EE0-9ED6-4812-8852-38EB4BEA97E6

Q36493279-5DFA5457-3B9B-47E5-A22E-55539311ECCB

Q36493279-7C405E40-1CA7-4D04-BBA3-67CF30751622

P304

Q36493279-3B22CC77-002F-49CA-B3C7-6D86185E0DC2

P31

Q36493279-A35D9B41-0225-4FBD-9302-ED0E2B7A2A1F

P356

Q36493279-D01A47CB-B449-4D6C-BA25-E987B858B8AA

P407

Q36493279-57E115A5-4CC8-4907-862B-D993C8129D3E

P433

Q36493279-0F728E44-8BF0-44BE-8A5C-25B68833EE74

P478

Q36493279-A18E07AF-9DE8-4301-9234-F2B58E8942F4

P50

Q36493279-592D02C4-7C50-46ED-A724-F91FCA370EC5

Q36493279-DE5725DC-D117-437A-8D97-9089A2E25019

P577

Q36493279-C17FF808-20E7-4BDD-82E1-0E952471100A

P698

Q36493279-2D5C61D1-8277-4FA0-87DE-EC1EB58908DC

P921

Q36493279-94F23684-4514-45AC-83F7-D72CF1CE986B

P932

Q36493279-F340DE45-4601-4B94-B7EC-A81654CB4EE5

P356

PAS.0B013E31826CABBD

P1433

The American Journal of Surgical Pathology

P1476

BRCA1 immunohistochemistry in ...... n high-grade serous carcinomas

@en

P2093

Andrew Berchuck

http://www.w3.org/2001/XMLSchema#string

Angeles Alvarez Secord

http://www.w3.org/2001/XMLSchema#string

Douglas A Levine

http://www.w3.org/2001/XMLSchema#string

Ethan Cerami

http://www.w3.org/2001/XMLSchema#string

Fanny Dao

http://www.w3.org/2001/XMLSchema#string

Karuna Garg

http://www.w3.org/2001/XMLSchema#string

Maria Bisogna

http://www.w3.org/2001/XMLSchema#string

Narciso Olvera

http://www.w3.org/2001/XMLSchema#string

P2860

Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability

BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer.

Integrated genomic analyses of ovarian carcinoma

Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis.

Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.

Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.

Cancer of the ovary.

Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.

Assays for hypermethylation of the BRCA1 gene promoter in tumor cells to predict sensitivity to PARP-inhibitor therapy

Testing women with endometrial cancer to detect Lynch syndrome.

P304

138-146

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/PAS.0B013E31826CABBD

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P50

Robert A Soslow

Nikolaus Schultz

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23232854

http://www.w3.org/2001/XMLSchema#string

P921

immunohistochemistry

P932

3531916

http://www.w3.org/2001/XMLSchema#string